Fadl, Ahmed AbdelSamie and Alghamdi, Hussam Yahya Abdullah and Ashgan, Baraah Atef Madani and Alasmari, Nuha Saad H. and Alwahbi, Sultan Salman and Alkhamis, Bayan Anwar and Almutairi, Sultan Meshal and Albeladi, Quds Hussain and Alotaibi, Ghadeer Abdullah and Alotaibi, Rawan Obaid and Bamousa, Reema Mohammed and Alzamami, Jana Fahad (2021) Overview on Pediatric Myelodysplastic Syndrome: A Review. Journal of Pharmaceutical Research International, 33 (56B). pp. 1-7. ISSN 2456-9119
4687-Article Text-6774-1-10-20221006.pdf - Published Version
Download (317kB)
Abstract
Myelodysplastic syndrome (MDS) is a set of clonal bone marrow diseases in children that are characterised by peripheral cytopenia, dysplastic alterations in the bone marrow, and inefficient hematopoiesis. MDS is uncommon in children, with just 1-4 occurrences per million children afflicted. Adults, particularly the elderly, are more susceptible to the disease. Some hereditary disorders, such as Fanconi's anaemia, Shwachman's, and Down's syndromes, are known to predispose children to developing MDS. JCML and monosomy 7 syndrome are the two most frequent paediatric MDS types, both of which affect children in their early years. Approximately 20% of juvenile myelodysplastic syndrome (MDS) cases are discovered by chance during normal laboratory testing or during the course of a suspected hereditary bone marrow failure (IBMF). Differentiating MDS with low blast numbers from aplastic anaemia (AA) and MDS with excess blasts from AML are the two key diagnostic issues in this condition. Bone marrow transplantation and stem cell transplantation is the treatment of choice in most cases. In this article we discuss the disease epidemiology, diagnosis, and treatment.
Item Type: | Article |
---|---|
Subjects: | Pacific Library > Medical Science |
Depositing User: | Unnamed user with email support@pacificlibrary.org |
Date Deposited: | 06 May 2023 07:03 |
Last Modified: | 28 May 2024 06:10 |
URI: | http://editor.classicopenlibrary.com/id/eprint/412 |